Asgard Therapeutics develops an off‑the‑shelf gene‑therapy, AT‑108, that uses a replication‑deficient adenoviral vector to deliver proprietary transcription factors directly into tumor cells. The vector reprograms cancer cells in situ into dendritic‑like antigen‑presenting cells, restoring tumor immunogenicity and triggering a personalized cytotoxic T‑cell response without ex vivo manufacturing. This platform aims to provide a scalable, logistics‑simplified cancer immunotherapy for solid‑tumor indications.
Funding
$32.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
3OJJRIFounders
Product
Problem
Cancer cells often evade immune detection by down‑regulating antigen presentation, and existing cell‑based immunotherapies face manufacturing complexity and limited scalability. Consequently, many patients do not achieve durable responses to current immunotherapies.
Solution
Asgard Therapeutics addresses this gap with AT‑108, an off‑the‑shelf gene‑therapy that delivers a replication‑deficient adenoviral vector encoding three proprietary transcription factors directly into tumor cells. The vector reprograms the transduced cancer cells in situ into conventional type‑1 dendritic‑like cells (cDC1), restoring their ability to process and present tumor antigens. This “Trojan‑DC” approach triggers a personalized, tumor‑specific cytotoxic T‑cell response without the need for ex vivo cell manufacturing or prior antigen identification. Preclinical data show dose‑dependent tumor regression, synergistic activity with checkpoint inhibitors, and systemic immunity across multiple solid‑tumor models. The platform is designed for scalable production and broad applicability, positioning AT‑108 as a first‑in‑class, personalized off‑the‑shelf cancer immunotherapy.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology therapeutics, as well as academic and clinical research groups seeking novel immunotherapy platforms for solid‑tumor indications.
Features
- Replication‑deficient adenoviral vector delivering a defined set of reprogramming transcription factors to tumor cells in vivo
- Direct conversion of tumor cells into cDC1‑like antigen‑presenting cells, restoring tumor immunogenicity
- Off‑the‑shelf formulation eliminates patient‑specific manufacturing and logistics challenges
- Demonstrated monotherapy efficacy and synergistic enhancement with immune‑checkpoint blockade in preclinical models
- Broad tumor‑type activity with systemic, dose‑dependent anti‑tumor responses and abscopal effects
- Integrated biomarker program identifying pharmacodynamic signatures of dendritic reprogramming and T‑cell activation